The prevalence of Alzheimers Disease and Associated Indications - Exceptional Level of First-in-Class Innovation within AD, and Diverse Range of Therapies in Development for Disorders Such as Anxiety and Depression
"The Report Frontier Pharma: Alzheimers Disease and Associated Indications - Exceptional Level of First-in-Class Innovation within AD, and Diverse Range of Therapies in Development for Disorders Such as Anxiety and Depression provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"Alzheimer’s disease (AD), the most common form of dementia, is a progressive, neurodegenerative and currently incurable disease characterized by loss of memory and other mental abilities. It has a devastating impact on independence and quality of life, with patients requiring full-time care in the later disease stages. In addition to cognitive impairment, AD is associated with behavioral and psychological changes, which often represent the greatest challenges for patients and caregivers.
The prevalence of AD is escalating rapidly, largely owing to aging populations, as advancing age is the most important epidemiological risk factor for the disease. This will amplify the already substantial societal and economic costs of the disease over the coming years. This has led to high levels of R&D investment over the past two decades, but clinical trial failure rates within the indication are extremely high and treatment options remain limited. There are no disease-modifying therapies for AD, and current approaches can only temporarily slow the worsening of symptoms.
Get Sample Copy Of This Report @
www.marketresearchreports.biz/sample/sample/1135804
The report focuses on AD alongside four key associated behavioral and psychological indications: anxiety, depression, psychosis and insomnia. These four conditions are highly prevalent in AD and contribute substantially to the disease burden.
Scope
Unmet need is extremely high in AD, with behavioral and psychological complications contributing significantly to the disease burden
What are the most important etiological risk factors and pathophysiological processes implicated in AD?
What is the current treatment algorithm?
How common are anxiety, depression, psychosis and insomnia in AD?
View Report @ http://www.marketresearchreports.biz/analysis/1135804
The AD pipeline is large and contains a very high proportion of first-in-class product innovation
Which molecule types and molecular targets are most prominent across AD and its associated indications?
What are the connections, in terms of first-in-class innovation, between AD and its associated indications?
Which first-in-class targets are most promising?
How does the level of first-in-class innovation differ between products in development for anxiety, depression, psychosis and insomnia?
How does first-in-class target diversity differ by stage of development and molecular target class?
The deals landscape is active and dominated by G-protein coupled receptor (GPCR)-targeting products
Which indications attract the highest deal values?
How has deal activity fluctuated over the past decade?
Which first-in-class pipeline products have no prior involvement in licensing or co-development deals?
Reasons to buy
This report will allow you to -
Appreciate the current clinical and commercial landscapes by considering disease pathogenesis, etiology, epidemiology, symptoms, diagnosis and treatment options.
Identify leading products and key unmet needs within the market.
Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target.
Assess the therapeutic potential of first-in-class targets. Using proprietary matrix assessments, first-in-class targets in the pipeline have been assessed and ranked according to clinical potential. Individual matrix assessments are provided for targets identified in the pipeline for AD, anxiety, depression, psychosis and insomnia. Promising early-stage first-in-class targets are reviewed in greater detail.
Consider first-in-class pipeline products with no prior involvement in licensing and co-development deals that may represent potential investment opportunities.
About us
MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.
Contact
Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
Website: http://www.marketresearchreports.biz/
E: sales@marketresearchreports.biz
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release The prevalence of Alzheimers Disease and Associated Indications - Exceptional Level of First-in-Class Innovation within AD, and Diverse Range of Therapies in Development for Disorders Such as Anxiety and Depression here
News-ID: 569386 • Views: …
More Releases from MarketResearchReports.biz
Global Automotive Augmented Reality and Virtual Reality Market Breakdown Data by …
MarketResearchReports.Biz has recently announced the Latest industry research report on: “Global Automotive Augmented Reality and Virtual Reality Market Insights, Forecast to 2025”
Augmented reality (AR) is a technology that adds on or layers digital media, such as touch feedback, graphics, 3D models, and sound, on a real world environment to enhance user experience and interaction. Virtual reality (VR) is a computer simulated reality that is achieved through replicating an environment…
Global Artificial Intelligence in Transportation Market Breakdown Data by Region …
MarketResearchReports.Biz has recently announced the Latest industry research report on: “Global Artificial Intelligence in Transportation Market Insights, Forecast to 2025”
Global Artificial Intelligence in Transportation market size will reach million US$ by 2025, from million US$ in 2017, at a CAGR of during the forecast period. In this study, 2017 has been considered as the base year and 2018-2025 as the forecast period to estimate the market size for Artificial…
Global Automotive Wind Tunnel Testing Equipment Market Forecast to 2025: By Prod …
MarketResearchReports.Biz has recently announced the Latest industry research report on: “Global Automotive Wind Tunnel Testing Equipment Market Insights, Forecast to 2025”
Global Automotive Wind Tunnel Testing Equipment market size will reach million US$ by 2025, from million US$ in 2017, at a CAGR of during the forecast period. In this study, 2017 has been considered as the base year and 2018-2025 as the forecast period to estimate the market size…
Global Automotive Beauty Industry Analysis and Forecast 2018-2025
MarketResearchReports.Biz has recently announced the Latest industry research report on: “Global Automotive Beauty Market Insights, Forecast to 2025”
This industry study presents the global Automotive Beauty market size, historical breakdown data (2013-2018) and forecast (2018-2025). The Automotive Beauty production, revenue and market share by manufacturers, key regions and type;
The consumption of Automotive Beauty in volume terms are also provided for major countries (or regions), and for each application and product…
More Releases for Alzheimers
Alzheimers Disease Treatment Market Size, Report 2022-2030
Acumen Research and Consulting has announced the addition of the "Alzheimer's Disease Treatment Market" report to their offering.
The Alzheimer's Disease Treatment Market Report 2030 is an in depth study analyzing the current state of the Alzheimer's Disease Treatment Market. It provides brief overview of the market focusing on definitions, market segmentation, end-use applications and industry chain analysis. The study on Alzheimer's Disease Treatment Market provides analysis of global market covering…
Rugged Expansion Foreseen by Alzheimers Disease Market
ResearchMoz include new market research report "Frontier Pharma: Alzheimers Disease and Associated Indications - Exceptional Level of First-in-Class Innovation within AD, and Diverse Range of Therapies in Development for Disorders Such as Anxiety and Depression" to its huge collection of research reports.
Alzheimer’s disease (AD), the most common form of dementia, is a progressive, neurodegenerative and currently incurable disease characterized by loss of memory and other mental abilities. It has a…
Alzheimers Disease Therapeutics Market - Technological Advancements Enhancing th …
Alzheimer’s disease is a neurodegenerative, progressive, non-reversible disorder. Alzheimer’s disease is caused due to abnormal functioning of brain cells i.e. failure of synaptic transmission, resulting in the loss of cognitive functions. Some of the signs and symptoms of alzheimer’s disease are memory loss, insomnia, repetitive movements, agitation, anxiety, depression and loss of reasoning abilities. All memory and mental functioning may be lost in advanced stages of the disease. Alzheimer’s disease…
Alzheimers Drug Market Size, Share and Forecast till 2022
Alzheimers Drug Report by Material, Application, and Geography - Global Forecast to 2021 is a professional and in-depth research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, united Kingdom, Japan, South Korea and China).
Request Sample Copy of the Business Report @ https://www.worldwidemarketreports.com/sample/26138
The report firstly introduced the Alzheimers Drug basics: definitions, classifications, applications and…
Global Alzheimers Disease Drug Market Professional Survey Report 2017
This report studies Alzheimers Disease Drug in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022.
This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering
Allergan
Eisai
Novartis
Daiichi Sankyo
Merz Pharma
Pfizer
Johnson & Johnson
Lundbeck.
Get free PDF brochure of the report at: https://www.qyresearchreports.com/sample/sample.php?rep_id=1339210&type=E
On the…
Alzheimers Disease - Heat Map and Analysis
Albany, NY, Feb 27, 2017: Alzheimers disease (AD) is an irreversible, progressive neurodegenerative disease, characterized by cognitive impairment, memory loss and functional decline. The pathological features of AD comprise a complex set of histopathological changes within the brain. Symptoms typically begin to first appear in patients in their mid-sixties, and appear in varying stages. The effects of AD, particularly at an advanced stage, are devastating to patients and their caregivers,…